Famciclovir

Confirm delete?

Famciclovir

Zoom

Cat No: 23834

Biochemicals - Anti-Infection

Famciclovir is an orally bioavailable prodrug form of the antiviral guanosine analog penciclovir (Item No. 22918).{39519} Famciclovir is rapidly deacetylated and oxidized in vivo to form penciclovir, which is active against clinical isolates of herpes...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol, 1,3-diacetate

Correlated keywords:

HSV2 HSV1 Famvir BRL42810 FCV Famcivir Famcyclovir Famtrex Famvir Fanxiluowei

Product Overview:
Famciclovir is an orally bioavailable prodrug form of the antiviral guanosine analog penciclovir (Item No. 22918).{39519} Famciclovir is rapidly deacetylated and oxidized in vivo to form penciclovir, which is active against clinical isolates of herpes simplex virus 1 (HSV-1), HSV-2, and varicella-zoster virus (VZV) in a plaque reduction assay with IC50 values of 1.6, 6, and 12 μM, respectively. Both famciclovir and the product of its deacetylation, 6-deoxypenciclovir, are oxidized in vitro by human, guinea pig, and rat liver aldehyde oxidase, with 6-deoxypenciclovir being converted to penciclovir.{39520} Peak plasma concentrations of penciclovir (mean 3.5 μg/ml) are reached 0.5 hours after oral administration of famciclovir (40 mg/kg) in rats.{39521} Famciclovir (25 mg/kg) has a longer half-life in dogs, with peak concentrations of penciclovir (mean 4.4 μg/ml) in plasma occurring after 3 hours.

Size	25 mg
Shipping	dry ice
CAS Number	104227-87-4
Molecular Formula	C₁₄H₁₉N₅O₄
SMILES	NC1=NC(N(CCC(COC(C)=O)COC(C)=O)C=N2)=C2C=N1
Molecular Weight	321,3
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2921.49
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.